Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Silo Pharma engaged partner Resyca to conduct a robustness study evaluating the microchip-based nasal spray system for its lead asset SPC-15. The study assesses device performance consistency and formulation stability over a 30-day period, intended to support a planned FDA Type C meeting request.
Key figures
- Drug Name
- SPC-15
- Stability duration
- 30-day
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.